Xenon Pharmaceuticals
XENE · NASDAQ
Bulios Fair Price
$19.55
46.4% downside
Current Price
$36.44
According to Bulios Fair Price, XENE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Xenon Pharmaceuticals is a biotechnology company focused on developing innovative therapies for the treatment of neurological and genetic disorders. The company specializes in discovering and developing new drugs that target specific genetic pathways and ion channels critical for the proper functioning of the nervous system. Xenon focuses on rare and difficult-to-treat disorders, such as epilepsy and various neurological conditions caused by genetic mutations. The company utilizes advanced technologies to accelerate the development of these therapeutics and improve the lives of patients suffering from these diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Ian C. Mortimer
Employees
364
Headquarters
Burnaby
Upcoming events
Earnings
Upcoming earnings report